| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
54,670,000 |
| Market
Cap: |
492.03(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.42 - $16.69 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 21.5 |
| Insider 6 Months : 22.2 |
| Insider 3/6 Months : 44.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Astria Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Co.'s primary product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. STAR-0215 is in preclinical development.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,481,350 |
3,221,350 |
4,295,958 |
5,204,223 |
| Total Buy Value |
$29,999,522 |
$34,587,522 |
$41,587,519 |
$51,587,517 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
3 |
4 |
| Total Shares Sold |
19,200 |
20,000 |
20,000 |
20,000 |
| Total Sell Value |
$238,491 |
$247,303 |
$247,303 |
$247,303 |
| Total People Sold |
1 |
1 |
1 |
1 |
| Total Sell Transactions |
2 |
3 |
3 |
3 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Morabito Christopher |
Chief Medical Officer |
• – – |
2024-04-01 |
4 |
AS |
$13.59 |
$135,939 |
D/D |
(10,000) |
0 |
|
-33% |
|
| Morabito Christopher |
Chief Medical Officer |
• – – |
2024-04-01 |
4 |
OE |
$3.87 |
$38,700 |
D/D |
10,000 |
10,000 |
|
- |
|
| Edelman Joseph |
Director |
– • – |
2024-02-01 |
4 |
B |
$12.09 |
$29,999,522 |
I/I |
2,481,350 |
4,873,721 |
2.1 |
-32% |
|
| Morabito Christopher |
Chief Medical Officer |
• – – |
2024-01-29 |
4 |
AS |
$11.15 |
$102,552 |
D/D |
(9,200) |
0 |
|
-26% |
|
| Morabito Christopher |
Chief Medical Officer |
• – – |
2024-01-29 |
4 |
OE |
$3.87 |
$35,604 |
D/D |
9,200 |
9,200 |
|
- |
|
| Morabito Christopher |
Chief Medical Officer |
• – – |
2024-01-26 |
4 |
AS |
$11.02 |
$8,812 |
D/D |
(800) |
0 |
|
-16% |
|
| Morabito Christopher |
Chief Medical Officer |
• – – |
2024-01-26 |
4 |
OE |
$3.87 |
$3,096 |
D/D |
800 |
800 |
|
- |
|
| Edelman Joseph |
Director |
– • – |
2023-12-21 |
4 |
B |
$6.20 |
$4,588,000 |
I/I |
740,000 |
2,392,371 |
2.1 |
47% |
|
| Edelman Joseph |
Director |
– • – |
2023-10-16 |
4 |
B |
$6.51 |
$6,999,997 |
I/I |
1,074,608 |
1,611,699 |
2.1 |
122% |
|
| Edelman Joseph |
Director |
– • – |
2022-12-19 |
4 |
B |
$11.01 |
$9,999,998 |
I/I |
908,265 |
1,038,309 |
2.1 |
24% |
|
| Violin Jonathan |
Director |
– • – |
2021-09-20 |
4 |
A |
$0.00 |
$0 |
D/D |
263,321 |
263,321 |
|
- |
|
| Violin Jonathan |
Director |
– • – |
2021-09-20 |
4 |
D |
$0.00 |
$0 |
I/I |
(263,321) |
0 |
|
- |
|
| Edelman Joseph |
Director |
– • • |
2021-01-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,476,924 |
|
- |
|
| Violin Jonathan |
Director |
– • – |
2021-01-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
543,373 |
|
- |
|
| Callori Fred |
Director |
– • – |
2021-01-28 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,476,924 |
|
- |
|
| Laufer Ron |
Director |
– • • |
2015-06-30 |
4 |
B |
$12.00 |
$2,681,268 |
I/I |
223,439 |
1,632,652 |
2.25 |
- |
|
| Laufer Ron |
Director |
– • • |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,409,213 |
1,409,213 |
|
- |
|
| Sv Life Sciences Fund V Strategic Partners, L.p. |
10% Owner |
– – • |
2015-06-30 |
4 |
B |
$12.00 |
$4,693,080 |
I/I |
391,090 |
59,139 |
1.5 |
- |
|
| Sv Life Sciences Fund V Strategic Partners, L.p. |
10% Owner |
– – • |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
2,466,577 |
51,045 |
|
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2015-06-30 |
4 |
B |
$12.00 |
$2,681,268 |
D/D |
223,439 |
1,632,652 |
2.45 |
- |
|
| Medimmune Ventures, Inc. |
10% Owner |
– – • |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
1,409,213 |
1,409,213 |
|
- |
|
| Jirousek Michael |
Chief Scientific Officer |
• – – |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
67,067 |
246,093 |
|
- |
|
| Clarus Ventures Ii, Llc |
10% Owner |
– – • |
2015-06-30 |
4 |
B |
$12.00 |
$4,520,340 |
D/D |
376,695 |
2,752,488 |
2.45 |
- |
|
| Clarus Ventures Ii, Llc |
10% Owner |
– – • |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,375,793 |
2,375,793 |
|
- |
|
| Modi Rick |
Chief Business Officer |
• – – |
2015-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,094 |
4,094 |
|
- |
|
33 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.17 (1.85%) 
